Research Article

Glyoxylate, a New Marker Metabolite of Type 2 Diabetes

Victoria J. Nikiforova,1,2 Pieter Giesbertz,3 Jan Wiemer,4,5 Bianca Bethan,4 Ralf Looser,4 Volker Liebenberg,1,5 Patricia Ruiz Noppinger,1,6 Hannelore Daniel,3 and Dietrich Rein1

1 Metanomics Health GmbH, 10589 Berlin, Germany
2 Timiryazev Institute of Plant Physiology, Russian Academy of Sciences, Moscow 127276, Russia
3 ZIEL Research Center for Nutrition and Food Sciences, Biochemistry Unit, Technische Universität München, 85354 Freising, Germany
4 metanomics GmbH, 10589 Berlin, Germany
5 Thermo Fisher Scientific, Clinical Diagnostics, BRAHMS GmbH, 16761 Hennigsdorf, Germany
6 Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany

Correspondence should be addressed to Dietrich Rein; dietrich.rein@metanomics-health.de

Received 3 June 2014; Revised 2 October 2014; Accepted 14 October 2014; Published 27 November 2014

Academic Editor: Shi Fang Yan

Copyright © 2014 Victoria J. Nikiforova et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 2 diabetes (T2D) is characterized by a variety of metabolic impairments that are closely linked to nonenzymatic glycation reactions of proteins and peptides resulting in advanced glycation end-products (AGEs). Reactive aldehydes derived from sugars play an important role in the generation of AGEs. Using metabolite profiling to characterize human plasma from diabetic versus nondiabetic subjects we observed in a recent study that the reactive aldehyde glyoxylate was increased before high levels of plasma glucose, typical for a diabetic condition, could be measured. Following this observation, we explored the relevance of increased glyoxylate in diabetic subjects and in diabetic C57BLKS/J-Lepr<sub>db/db</sub>−/− mice in the pathophysiology of diabetes. A retrospective study using samples of long-term blood donors revealed that glyoxylate levels unlike glucose levels became significantly elevated up to 3 years prior to diabetes diagnosis (difference to control <i>P=0.034</i>). Elevated glyoxylate levels impact on newly identified mechanisms linking hyperglycemia and AGE production with diabetes-associated complications such as diabetic nephropathy. Glyoxylate in its metabolic network may serve as an early marker in diabetes diagnosis with predictive qualities for associated complications and as potential to guide the development of new antidiabetic therapies.

1. Introduction

Despite the long history of research on T2D, the knowledge about metabolic impairments and molecular mechanisms that participate in the development of diabetes is still limited. Central to diabetes pathology is a chronic hyperglycemia promoting the production of advanced glycation end-products (AGEs) that associate with inflammation and cause micro- and macrovascular damage [1] and with diabetic nephropathy, a severe and costly endpoint [2]. Preventing chronic hyperglycemia is the most critical goal of today’s guidelines in preventing diabetes complications. Still, insulin resistance and insulin deficiency cause major impairments in the numerous metabolic pathways contributing to disease pathology.

Metabolite profiling approaches in plasma samples from subjects with impaired glucose tolerance and T2D revealed distinct changes in various metabolite classes [3–6]. Recently, Wang-Sattler et al. [7] described glycine and lysophosphatidylcholine levels as predictors for impaired glucose tolerance and T2D and those were associated with genetic variation in proteins of related pathways. Floegel et al. [8] identified increased serum hexose, phenylalanine, tyrosine, branched chain amino acids, and diacyl-phosphatidylcholine levels as closely associated with an increased risk of T2D. Wang et al. [9] described ketoacid derivatives of the branched chain amino acids as sensitive plasma indicators of insulin resistance and Sailer et al. [10] proposed citrulline to be part of obesity-dependent metabolic impairments. We focused on
towards improved diagnosis and novel treatment approaches.

Glyoxylate is a diabetes marker useful for further development in the context of its metabolic network. Our results suggest that in a mouse model and discuss the role of this aldehyde in a better understanding of disease progression and strategies for interferences. Animal models such as the C57BLKS/J-Lepr\(d\bar{b}/d\bar{b}^{−/−}\) mouse model, whose diabetic phenotype resembles diabetes mellitus in man [19], have been useful in exploring diabetes pathology. Here we further investigate glyoxylate in a mouse model and discuss the role of this aldehyde in the context of its metabolic network. Our results suggest that glyoxylate is a diabetes marker useful for further development towards improved diagnosis and novel treatment approaches.

2. Materials and Methods

2.1. Ethics Statement. Human experimental protocols of the studies herein described were approved by the responsible ethics committee and conducted according to the principles of the Declaration of Helsinki. All subjects participating in the sample collection study gave written informed consent. The address of the ethics committee was Ethik-Kommission der Bayerischen Landesärztekammer, Mühlbaurstrasse 16, 81677 München, Germany, approval from July 27th, 2008, number 08055. Animal care and use for this study was approved by the Veterinary Inspection Services, Section of Animal Protection, the Freising District Office, 85356 Freising, Germany (reference number: 32-568-2).

2.2. Prospective Clinical Study. Blood plasma samples were obtained from a cohort of the Bavarian Red Cross Blood Donation Service (Blutspendendienst des Bayerisches Rotes Kreuz, Munich, Germany) within a collaborative diabetes risk sample collection project cofunded by the “Bayerische Forschungsstiftung” (AZ 773-707). Overall 478 out of the 789 study participants were included in the metabolite profiling analysis of the prospective study part. Participants were categorized as newly identified diabetic subjects based on fasting plasma glucose (FPG) > 7.0 mmol/L or by an oral glucose tolerance test (OGTT) with plasma glucose levels 2 hours after the standardized 75 g oral glucose challenge (2HGP) of \( \geq 11.1 \text{ mmol/L}\) [20]. Subjects at risk for diabetes were defined as those with impaired fasting glucose (IFG) levels of \( \geq 5.6 \) to \( < 7.0 \text{ mmol/L}\) and those with impaired glucose tolerance (IGT) levels of \( \geq 7.8 \) to \( < 11.1 \text{ mmol/L}\). Nondiabetic control subjects had glucose levels below these threshold levels. Nondiabetic control subjects were matched for gender, age, and BMI to the diabetic subjects and subjects at risk for diabetes. Data sets were analyzed by computing ANOVA models corrected for confounders. All samples collected were processed according to metabolomics-specific standard operating procedures and stored at \( \sim 80^\circ\)C until analysis.

2.3. Retrospective Clinical Study. Plasma samples were obtained from a subset of 243 subjects of the prospective study described above for whom nonfasting plasma samples were available from previous routine blood donations at 0, 1.5, 3, and 6 years prior to study inclusion and diabetes diagnosis. Categorization of these subjects was done based upon FPG and OGTT data from the prospective study. Enrolled were \( n = 55 \) diabetic subjects according to FPG and/or OGTT criteria for diabetes [20]. The remaining subjects were categorized as with increased risk for diabetes (\( n = 92 \)) and as nondiabetic subjects (\( n = 96 \)) according to the same criteria. All samples collected retrospectively were processed according to standard operating procedures by the Bavarian Red Cross Blood Donor Service and stored at \( \sim 42^\circ\)C until transfer to Metanomics Health.

2.4. Type 2 Diabetes Mouse Model. Male mutant C57BLKS/J-Lepr\(d\bar{b}/d\bar{b}^{−/−}\) (\(db/db^{−/−}\)) mice and respective male C57BLKS/J wild-type controls (\( n = 6 \) for both groups) were purchased from Charles River Laboratories at an age of five weeks. All mice had ad libitum access to food and water throughout the whole feeding period, were conventionally housed with at least two animals per cage, and were analyzed at an age of 20 weeks in nonfasting state. For standardization, all mice were given the same chemically-defined control diet (ssniff EF R/M Kontrolle). Body weight was measured weekly and blood glucose was measured shortly before sacrifice. Animals were anesthetized with isoflurane, blood was collected into EDTA-coated tubes via retro-orbital puncture, and animals were sacrificed using cervical dislocation. All mice were sacrificed between 9:00 A.M. and 10:00 A.M. Tissues (liver and quadriceps muscle) were collected, snap-frozen in liquid nitrogen, and ground prior to extraction of metabolites. Metabolite profiling results of \( db/db^{−/−} \) mice were analyzed against their black Kaliss (C57BLKS/J) wild-type control mice.

2.5. Metabolite Profiling. Two types of mass spectrometry analyses were applied to all samples: gas chromatography-mass spectrometry (GC/MS) and liquid chromatography-MS/MS for broad profiling as described previously [21]. Briefly, proteins were removed from plasma samples by precipitation prior to collection of polar and nonpolar fractions for both GC-MS and LC-MS/MS. For GC-MS analyses, the nonpolar fraction was treated with methanol under acidic conditions to yield the fatty acid methyl esters derived from both free fatty acids and hydrolyzed complex lipids. The polar and nonpolar fractions were further derivatized with O-methylhydroxylamine hydrochloride to convert oxo-groups to O-methylximes and subsequently with a silylating agent prior to GC-MS analysis. For LC-MS/MS analyses, both
analyses of samples available (or stored) at the biobank of the Blood Donation Service were from diabetes and diabetes risk subjects (\(n = 147\)).


\(\text{db/db}\) and degradation (n.s.: not significant and FC: fold-change (level) were detectable in fasting as well as in nonfasting plasma samples. Fasting plasma was obtained from diabetes and diabetes risk subjects blood plasma in type 2 diabetes and starts to rise in nonfasted subjects later diagnosed as prediabetic or diabetic up to 3 years prior to T2D.


Quantification was performed with external calibration using a standard. Accuracy was confirmed by spiking experiments with three characteristic mass fragments were monitored. High performance LC (HPLC) was performed by gradient fraction were reconstituted in appropriate solvent mixtures. High performance LC (HPLC) was performed by gradient elution on reversed phase separation columns. Mass spectrometric detection technology was applied as targeted and high sensitivity "multiple reaction monitoring" profiling in parallel to a full screen analysis. To account for inter- and intrastudy variation in GC-MS and LC-MS/MS profiling, data were normalized to the median of reference samples derived from a pool formed from aliquots of all samples. Pooled reference samples were run in parallel through the whole process. Key analytical parameters determined within method development and reviewed within the present study were taken into account to specify high quality metabolites, herein termed as semiquantitative metabolites.

Determination of the absolute concentration of glyoxylate in selected samples was performed by GC-SIM-MS in a single ion monitoring mode. The derivatized samples were separated by gas chromatography, and in the mass spectrometer three characteristic mass fragments were monitored. Quantification was performed with external calibration using stable isotopically labeled \((^{13}C_2)\)-glyoxylate as internal standard. Accuracy was confirmed by spiking experiments with a concentration range of 0.55–80 \(\mu\text{mol/L}\) spiked glyoxylate. Precision of glyoxylate quantification was 7%, limit of detection was 5.7 \(\mu\text{mol/L}\), and limit of quantification was 21.1 \(\mu\text{mol/L}\).

2.6. Statistical Analysis. Plasma samples from clinical studies were analyzed in a randomized sequence design with pooled samples (i.e., “pool”) generated from aliquots of each sample as a reference. Following comprehensive analytical validation steps, the raw peak data for each analyte was normalized to the median of the pool samples per analytical sequence to account for process variability (i.e., “pool-normalized ratios”). For identification of diabetes-associated differences between groups for each metabolite a univariate linear model was applied to the log-transformed pool-normalized ratios. The model was corrected for the fixed confounders age, gender, and BMI diabetes group. In the historic dataset, a mixed linear model including the owner ID as a random factor as well as the fixed factors time point of sample collection and the interaction between the time point of sample collection and diagnostic group in addition to the other confounders was calculated. Significances for differences in metabolite ratios between groups were assessed using \(P\) values of Students’ \(t\)-statistics.

3. Results

3.1. Prospective Clinical Study. Fifty-eight participants were categorized as newly identified diabetic subjects based on FPG or 2HPG. The largest group consisted of subjects at risk for diabetes with IFG and/or IGT (\(n = 243\)), whereas \(n = 177\) nondiabetic control subjects were included. Metabolomic marker discovery applying our metabolite profiling approach for diabetes screening revealed glyoxylate in addition to previously described metabolite markers as an early diagnostic metabolite. Curation of the profiling results confirmed glyoxylate elevated in diabetic and prediabetic subjects with a diabetic phenotype compared to controls (13%, \(P = 0.017\)) similar to the elevation of glucose (12%, \(P < 0.001\)) (Table 1).

### Table 1: Comparison of \(\text{db/db}\) and wild-type mice for plasma and tissue levels of glyoxylate and metabolites involved in glyoxylate synthesis or degradation (n.s.: not significant and FC: fold-change \(\text{db/db}\) relative to wild-type).

| Metabolite      | Plasma | Liver | Quadriceps muscle |
|-----------------|--------|-------|-------------------|
| Glucose         | 2.15   | 1.39  | 2.23              |
| Glyoxylate      | 6.06   | 1.05  | 0.67              |
| Glycine         | 1.13   | n.s.  | Not detected      |
| 4-Hydroxyproline| 0.81   | 0.62  | 0.49              |

Table 2: Comparison of \(\text{db/db}\) and wild-type mice for plasma and tissue levels of glyoxylate and metabolites involved in glyoxylate synthesis or degradation (n.s.: not significant and FC: fold-change \(\text{db/db}\) relative to wild-type).

| Metabolite       | Study condition | Fasting plasma | Nonfasting plasma |
|------------------|-----------------|----------------|-------------------|
|                  | Years prior to diagnosis of diabetes and diabetes risk | Fasting plasma | Nonfasting plasma |
|                  | Glucose         | 0              | 1.5              | 3               | 6               |
|                  | Glyoxylate      | 1.12*          | 1.08***          | 1.08***         | 1.07            | 1.01            |
|                  |                 | <0.001         | 0.059            | 0.060           | 0.106           | 0.810           |

\(* P < 0.01, ** P < 0.05, *** P < 0.10\).

### Table 2: Comparison of \(\text{db/db}\) and wild-type mice for plasma and tissue levels of glyoxylate and metabolites involved in glyoxylate synthesis or degradation (n.s.: not significant and FC: fold-change \(\text{db/db}\) relative to wild-type).

| Metabolite       | Study condition | Fasting plasma | Nonfasting plasma |
|------------------|-----------------|----------------|-------------------|
|                  | Glucose         | 0              | 1.5              | 3               | 6               |
|                  | Glyoxylate      | 1.12*          | 1.08***          | 1.08***         | 1.07            | 1.01            |
|                  |                 | <0.001         | 0.059            | 0.060           | 0.106           | 0.810           |

\(* P < 0.01, ** P < 0.05, *** P < 0.10\).
### Figure 1: Correlation matrix with glyoxylate and precursors/products of glyoxylate metabolism.

Kendall’s tau correlations between metabolite levels of glyoxylate, glycine and 4-hydroxyproline in liver (L), muscle (M), and plasma (P) and of glycolate in plasma are visualized. Blue shades represent positive correlations and red shades represent negative correlations. The more the circle is filled, the higher the absolute correlation is.

#### 3.2. Retrospective Clinical Study.

In plasma samples collected up to 6 years prior to the diagnosis of diabetes glyoxylate increased earlier than glucose and thus may qualify as early diabetes marker (3 years prior, \( P = 0.034 \); 1.5 years prior, \( P = 0.081 \); at the last blood donation before study recruitment and diabetes classification, \( P = 0.036 \); Table 1). The rise in glyoxylate in subjects prior to diabetes diagnosis paralleled that of glucose but appeared earlier in the retrospective study and may thus be capable of predicting T2D earlier than plasma glucose.

The C57BLKS/J-Lepr\(^{db/db}\) Diabetes Mouse Model. C57BLKS/J-Lepr\(^{db/db}\) / mice display a phenotype that resembles in many aspects that of humans with metabolic syndrome or diabetes characterized by hyperphagia, obesity, and hyperglycemia. Metabolite profiling revealed a 6-fold increase in plasma glyoxylate levels in \( db/db \) / mice as compared to wild-type animals (Table 2). Tissue metabolite profiling did not reveal a difference in liver glyoxylate levels but showed a small, yet significant, decrease in muscle glyoxylate levels (\( P = 0.025 \)). Putative precursors or products of glyoxylate production and utilization with strong concentration changes were identified. Glycine was strongly decreased in liver and muscle tissue, but it was not significantly changed in plasma. 4-Hydroxyproline was strongly decreased in liver, muscle, and plasma. Correlation analysis, however, did not reveal robust associations between plasma or tissue levels of glyoxylate, glycine, or 4-hydroxyproline (see Figure 1). Also, no strong correlation was found between glyoxylate and glycolate in plasma. Significant correlations were only observed for 4-hydroxyproline between plasma and tissues.

Principal component analysis of plasma metabolites however shows clear separation of wild-type and \( db/db \) / mice in the first dimension (Figure 2). Metabolites which
we confirmed strongly elevated plasma levels in 

to further investigate the source of high glyoxylate plasma 

the origins for the change in glyoxylate level observed in 

mice. Analysis of liver and muscle tissue could not identify 

been studied in cell cultures, animals, and humans [23, 24].

ated with the diabetic phenotype. Glyoxylate metabolism has 

plasma glyoxylate levels were also observed in the 

prior to the diagnosis of diabetes or prediabetes. Increased 

glyoxylate was found to associate with diabetes development and 

diabetes. In patients with newly diagnosed diabetes, glyoxy-

aldehyde—to the growing list of marker metabolites of 

the present study we add glyoxylate—a two-carbon reactive 

move into insulin resistance or diabetes. With the findings of 

in plasma glyoxylate levels could not be determined.

Pathways that lead to the production of glyoxylate are 
similar in microorganisms, fungi, plants, and some inver-
tebrates where the glyoxylate cycle is the prime source for 

the aldehyde during gluconeogenesis. In humans and higher 

organisms, glyoxylate is mainly a product of enzymatic gly-

colate oxidation in peroxisomes (Figure 4). This pathway is 

well-characterized as it is impaired in primary hyperoxaluria 

with abnormally increased production of oxalate for which 

glyoxylate is the major and direct precursor [25].

Glyoxylate is also a mitochondrial degradation product 
of hydroxyproline, which is derived from the dietary meat 

from endogenous collagen breakdown [26]. Diabetic 

db/db mice in our study showed very high glyoxylate 

levels in plasma but depressed levels in muscle tissue indi-

of muscle turnover or intramuscular glucose were 

not significant sources of glyoxylate. Another endogenous 

source of glyoxylate is glyoxal, which can be converted to 

oxalate [27], and glyoxylate has also been shown to be a 

source of glycine deamination catalyzed by kidney D-amino 

acid oxidase [13, 28]. In the db/db−/− mice, we found strong 

decreases compared to the wild-type mice for hydroxyproline 

in plasma, liver, and muscle and for glycine in liver and 

muscle. However, the lack of strong correlations to plasma 

and tissue glyoxylate levels suggests that these metabolites 
do not directly contribute to changes in plasma glyoxylate 

levels.

Interestingly, some precursors of glyoxylate are closely 

related to glucose metabolism products. Evidence that glu-

cose can be converted into glyoxylate was provided by 

experiments in HepG2 cells [27] which produce 13C2-labeled 
glycolate and 13C3-labeled oxalate from 13C6-labeled glucose. 

HepG2 cells can also convert glyoxylate into oxalate [29]. 

This feature of liver cells to derive glyoxylate from glucose 
may explain the correlation between plasma glucose and 
glyoxylate levels.

Glyoxylate is involved in major metabolic pathways; still, 
it has only been detected as a low abundant metabolite. 

We measured glyoxylate concentrations in human plasma of 
around 25 μmol/L in healthy subjects and >30 μmol/L in T2D 
subjects. Glyoxylate measured in human liver samples was 
as low as 128 pmol/mg protein and in HepG2 cells around 
38 pmol/mg protein corresponding to 6 μmol/L based on cell 
volume [29] suggesting that there is a regulation of cellular 
glyoxylate concentrations [30] allowing glyoxylate efflux into 
blood despite higher extracellular concentrations.

Amongst the pathways in which glyoxylate is metabo-
lized, the conversion to glycine catalyzed by alanine-
glyoxylate aminotransferase (AGT) in liver peroxisomes 
dominates. A second pathway is the oxidation of glyoxylate to 
oxalate by lactate dehydrogenase (LDH) with oxalate as a final 
metabolite in mammals. The third pathway is the enzymatic 
reduction of glyoxylate to glycolate by cytosolic glyoxylate 
reductase (GR), which occurs predominantly in the liver. 
Finally, the products oxalate and glycolate are then excreted 
with the urine [31].
It is well established that elevated plasma glucose levels cause damage of proteins by glycation and formation of AGEs. Most AGEs arise from reaction of the carbonyl group of reducing sugars such as glucose or from short-chain aldehydes with amino groups of proteins, lipids, and nucleic acids. Protein glycation reactions cause dysfunctions associated with various diseases in particular cardiovascular disease [32, 33] and alpha-oxoaldehydes, such as glyoxal, methylglyoxal, and 3-deoxyglucosone which are important precursors of advanced glycation adducts [34].

Glyoxal can be derived from oxidative fragmentation of a protein-sugar Schiff base, also known as the Namiki pathway [34], by oxidative degradation (autoxidation) of glucose via the Wollf pathway [35, 36] or by degradation of glycated proteins and AGEs [37] (Figure 4). In addition, it can derive from lipid peroxidation reactions [38–40], the autoxidation of glycolaldehyde [41], and other reactive intermediates within the Maillard reaction [42]. Glyoxal is also a by-product of fructose and xylulose metabolism [27, 43].

Alpha-oxoaldehydes are potent glycat ing agents with reactivity several thousand-fold higher than glucose in causing AGEs formation [44]. The reactivity of glyoxylate towards the production of AGEs has been shown with lysine, arginine, and glucosamine [45]. Compared to reducing sugars, glyoxylate was 60% more reactive than glucose or fructose and 20% more reactive than glyceraldehydes [45]. Glyoxylate also reacted when incubated with human serum albumin (HSA) producing approximately 10% of lysine and 20% of arginine side chain modifications. The fibrillar state as a measure of aggregation of a glyoxylic acid-modified HSA was shown to be enhanced, suggesting conformational changes of the protein to a degree of reduced biological functionality [46]. Thus, in addition to the well-known reactivity of glyoxal and methylglyoxal [47], glyoxylate appears to be involved in high glucose-induced protein damage by advanced glycation.

This calls for proper detoxification mechanisms in control of alpha-oxoaldehydes. Detoxification of glyoxal is primarily achieved by the glyoxalase system which consists of glyoxalase I, glyoxalase II, and glutathione [48]. It detoxifies alpha-oxoaldehydes to the corresponding aldonic acid. The product of glyoxal detoxification by the glyoxalase pathway is glycolate [49, 50], a substrate for glycolate oxidase (GO) to produce glyoxylic acid [51] (Figure 4). The glyoxalase system also detoxifies methylglyoxal to lactate.

An important second pathway is the detoxification of the AGE precursor glyoxal by aldo-keto reductases [51, 52] leading to glycolaldehyde, which can be converted to glyoxylate via glycolate by aldehyde dehydrogenase (ALDH) and glycolate oxidase (Figure 4). Aldehyde dehydrogenase is also involved in the third detoxification pathway that directly metabolizes the carbonyl substrate glyoxal in an irreversible

Figure 3: Variables plot showing plasma metabolites responsible for separation of individual mice. To visualize the strongest separators only, square correlations from both dimensions are summed for all metabolites and metabolites with a minimal sum of 0.6. The more distant the metabolites are from the circle center, the higher the correlation with the dimension (PC: phosphatidylcholine, LPC: lysophosphatidylcholine) is.
enzymatic oxidation reaction to glyoxylate. The appropriate enzyme was isolated from human liver and demonstrated to be involved in the removal of aldehydes [53]. All these pathways of glyoxal detoxification produce glyoxylate, either directly or indirectly, and thus link the changes in observed glyoxylate levels to pathways and mechanisms central to the pathophysiology of diabetes.

An important pathophysiological concept in the context of reactive aldehyde changes observed in this metabolite profiling study is the AGEs induced diabetic nephropathy [54, 55]. Chronic hyperglycemia is associated with diabetic nephropathy, and AGEs have been shown to be involved in its development and progression [56]. Glyoxylate may be directly and/or indirectly implicated in AGE mediated renal metabolic disorders. Direct implication would be by reacting with its α-oxoaldehyde group, indirectly by contributing a sensitive indicator of a glycating burden that accumulates in blood and causes damage to renal vessels.

Another aspect of diabetes-associated renal metabolic disorders to be reconsidered in light of glyoxylate is the implication of oxalate nephropathy. The findings that the direct oxalate precursor glyoxylate is at the same time a product of glyoxal detoxification provide a causal link between accumulation of AGEs and oxalate induced nephropathy leading to chronic renal failure, connecting AGEs mechanistically to renal pathophysiology. Indeed, association between diabetes and increased excretion of urinary oxalate was shown [57], and the finding that such increase is independent of the dietary oxalate intake gave rise to the hypothesis that it is due to diabetes pathophysiology [58]. However, recent clinical studies on the chemical composition of urinary stones did not reveal direct associations between oxalate stones and metabolic syndrome [59, 60].

Based on our metabolite profiling approaches in a mouse model of diabetes and in human samples and in view of
the scientific literature investigating the production, utilization, and role of glyoxylate, we have placed the new metabolic marker glyoxylate in context of diabetes pathology. The strength of this new marker is its link to protein-modifications causing long-term diabetes complications. Glyoxylate can thus be considered as “diabetes-metabolite” with predictive biomarker-quality.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

This paper is devoted to the memory of Henry Drysdale Dakin (1880–1952), a pioneer in glyoxylate biochemistry. The authors would like to thank the “Blutspendendienst des Bayerischen Roten Kreuzes gemeinnützige GmbH”, and in particular Dr. Silke Martin, for collaborating on the clinical sample collection and the access to their high quality biobank sample collection.

References

[1] D. V. Nguyen, L. C. Shaw, and M. B. Grant, “Inflammation in the pathogenesis of microvascular complications in diabetes,” Frontiers in Endocrinology, vol. 3, article 170, 2012.
[2] I. Gorbachinsky, H. Akpinar, and D. G. Assimos, “Metabolic syndrome and urologic diseases,” Reviews in Urology, vol. 12, pp. e157–e180, 2010.
[3] O. Fiehn, W. T. Garvey, J. W. Newman, K. H. Lok, C. L. Hoppel, and S. H. Adams, “Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women,” PLoS ONE, vol. 5, no. 12, Article ID e15234, 2010.
[4] I. R. Lanza, S. Zhang, L. E. Ward, H. Karakelides, D. Raftery, and K. S. Nair, “Quantitative metabolomics by 1H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes,” PLoS ONE, vol. 5, no. 5, Article ID e10538, 2010.
[5] K. Sunhe, C. Meisinger, A. Döring et al., “Metabolic footprint of diabetes: a multiplatform metabolomics study in an epidemiological setting,” PLoS ONE, vol. 5, no. 11, Article ID e10953, 2010.
[6] L. D. Roberts, A. Kouzman, and J. L. Griffin, “Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome,” The Lancet Diabetes & Endocrinology, vol. 2, no. 1, pp. 65–75, 2014.
[7] R. Wang-Sattler, Z. Yu, C. Herder et al., “Novel biomarkers for pre-diabetes identified by metabolomics,” Molecular Systems Biology, vol. 8, article 615, 2012.
[8] A. Floegel, N. Stefan, Z. Yu et al., “Identification of serum metabolites associated with risk of type 2 diabetes using a targeted metabolomic approach,” Diabetes, vol. 62, no. 2, pp. 639–648, 2013.
[9] T. J. Wang, D. Ngo, N. Psychogiou et al., “2-Aminoadipic acid is a biomarker for diabetes risk,” Journal of Clinical Investigation, vol. 123, no. 10, pp. 4309–4317, 2013.
[10] M. Sailer, C. Dahlhoff, P. Giesbertz et al., “Increased plasma citrulline in mice marks diet-induced obesity and may predict the development of the metabolic syndrome,” PLoS ONE, vol. 8, no. 5, Article ID e63950, 2013.
[11] I. Padberg, E. Peter, S. González-Maldonado et al., “A new metabolomic signature in type-2 diabetes mellitus and its pathophysiology,” PLoS ONE, vol. 9, no. 1, Article ID e85082, 2014.
[12] H. T. Clarke, “Henry drysdale dakin, 1880–1952,” The Journal of Biological Chemistry, vol. 198, no. 2, pp. 491–494, 1952.
[13] S. Ratner, V. Nocito, and D. E. Green, “Glycine oxidase,” The Journal of Biological Chemistry, vol. 152, pp. 119–133, 1944.
[14] E. Kun, “A study on the metabolism of glyoxal in vitro,” The Journal of Biological Chemistry, vol. 194, no. 2, pp. 603–611, 1952.
[15] K. E. Richardson and N. E. Tolbert, “Oxidation of glyoxylic acid to oxalic acid by glycolic acid oxidase,” The Journal of Biological Chemistry, vol. 236, pp. 1280–1284, 1961.
[16] S. Sawaki and K. Yamada, “Glyoxylate reductase activity of lactate dehydrogenase,” Nature, vol. 210, no. 31, p. 91, 1966.
[17] S. B. Mardashev and L. A. Semina, “Enzymic synthesis of glycine from glyoxylic acid,” Doklady Akademii Nauk SSSR, vol. 74, pp. 537–540, 1950.
[18] S. Song, “Can the glyoxylate pathway contribute to fat-induced hepatic insulin resistance?” Medical Hypotheses, vol. 54, pp. 739–747, 2000.
[19] K. P. Hummel, M. M. Dickie, and D. L. Coleman, “Diabetes, a new mutation in the mouse,” Science, vol. 153, no. 3740, pp. 1127–1128, 1966.
[20] American Diabetes Association, “Standards of medical care in diabetes—2010,” Diabetes Care, vol. 33, supplement 1, pp. S1–S61, 2010.
[21] D. Allaway, B. Kamlange, M. S. Gilham et al., “Effects of dietary glucose supplementation on the fasted plasma metabolome in cats and dogs,” Metabolomics, vol. 9, no. 5, pp. 1096–1108, 2013.
[22] W. J. Kim and C. Y. Park, “1,5-Anhydroglucitol in diabetes disease: the terminal metabolite that just won’t go away,” Nature, vol. 54, no. 3, pp. 513–520, 2011.
[23] R. P. Holmes, “Glycolate and glyoxylate metabolism in HepG2 cells,” The American Journal of Human Genetics, vol. 87, no. 3, pp. 392–399, 2010.
[24] J. Knight, D. G. Assimos, L. Easter, and R. P. Holmes, “Metabolism of fructose to oxalate and glycolate,” Hormone and Metabolic Research, vol. 42, no. 12, pp. 868–873, 2010.
[25] A. H. Neims and L. Hellerman, “Specificity of the D-amino acid oxidase in relation to glycine oxidase activity,” The Journal of Biological Chemistry, vol. 237, pp. C976–C978, 1962.
[26] P. S. Baker, S. D. Cramer, M. Kennedy, D. G. Assimos, and R. P. Holmes, “Glycolate and glyoxylate metabolism in HepG2 cells,” American Journal of Physiology: Cell Physiology, vol. 287, no. 5, pp. C1359–C1365, 2004.
[27] N. Schnedler, G. Burckhardt, and B. C. Burckhardt, “Glyoxylic acid is a substrate of the sulfate-oxalate exchanger, sat-1, and increases its expression in HepG2 cells,” Journal of Hepatology, vol. 54, no. 3, pp. 513–520, 2011.
[28] S. R. Marengo and A. M. Romani, “Oxalate in renal stone disease: the terminal metabolite that just won’t go away,” Nature Clinical Practice Nephrology, vol. 4, pp. 368–377, 2008.
[32] F. Piarulli, G. Sartore, and A. Lapolla, “Glyco-oxidation and cardiovascular complications in type 2 diabetes: a clinical update,” Acta Diabetologica, vol. 50, no. 2, pp. 101–110, 2013.

[33] A. Lapolla, S. Porcu, and P. Traldi, "Some views on proteomics in diabetes," Clinical Chemistry and Laboratory Medicine, vol. 49, no. 6, pp. 943–957, 2011.

[34] P. I. Thornalley, A. Langborg, and H. S. Minhas, "Formation of glyoxal, methylglyoxal and 8-deoxyglucose in the glycation of proteins by glucose," Biochemical Journal, vol. 344, no. 1, pp. 109–116, 1999.

[35] P. Thornalley, S. Wolff, J. Crabbe, and A. Stern, "The autoxidation of glyceraldehyde and other simple monosaccharides under physiological conditions catalysed by buffer ions," Biochimica et Biophysica Acta—General Subjects, vol. 797, no. 2, pp. 276–287, 1984.

[36] S. P. Wolff and R. T. Dean, “Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes,” Biochemical Journal, vol. 245, no. 1, pp. 243–250, 1987.

[37] N. Ahmed, R. Babaei-Jadidi, S. K. Howell, P. J. Beisswenger, and P. J. Thornalley, "Degradation products of proteins damaged by glycation, oxidation and nitrilation in clinical type 1 diabetes," Diabetologia, vol. 48, no. 8, pp. 1590–1603, 2005.

[38] M.-X. Fu, J. R. Requena, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R. Thorpe, "The advanced glycation end product, Nε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions," The Journal of Biological Chemistry, vol. 271, no. 17, pp. 9982–9986, 1996.

[39] A. Loidl-Stahlhöfen and G. Spitteler, „α-hydroxyaldehydes, products of lipid peroxidation," Biochimica et Biophysica Acta—Lipids and Lipid Metabolism, vol. 1211, no. 2, pp. 156–160, 1994.

[40] A. Mlakar and G. Spitteler, "Previously unknown aldehydic lipid peroxidation compounds of arachidonic acid," Chemistry and Physics of Lipids, vol. 79, no. 1, pp. 47–53, 1996.

[41] L. Benov and I. Fridovich, "Superoxide dependence of the toxicity of short chain sugars," The Journal of Biological Chemistry, vol. 273, no. 40, pp. 25741–25744, 1998.

[42] M. A. Glomb and V. M. Monnier, "Mechanism of protein modification by glyoxal and glycolaldehyde, reactive intermediates of the Maillard reaction," Journal of Biological Chemistry, vol. 270, no. 17, pp. 10017–10026, 1995.

[43] R. A. J. Conyers, R. Bais, and A. M. Rofe, "The relation of clinical catastrophes, endogenous oxalate production, and urolithiasis," Clinical Chemistry, vol. 36, no. 10, pp. 1717–1730, 1990.

[44] Z. Turk, "Glycotoxines, carbonyl stress and relevance to diabetes and its complications," Physiological Research, vol. 59, no. 2, pp. 147–156, 2010.

[45] U. Dutta, M. A. Cohenford, M. Guha, and J. A. Dain, "Non-enzymatic interactions of glyoxylate with lysine, arginine, and glucosamine: a study of advanced non-enzymatic glycation like compounds," Bioorganic Chemistry, vol. 35, no. 1, pp. 11–24, 2007.

[46] A. Schmitt, J. Schmitt, G. Münch, and J. Gasic-Milenovic, "Characterization of advanced glycation end products for biochemical studies: side chain modifications and fluorescence characteristics," Analytical Biochemistry, vol. 338, no. 2, pp. 201–215, 2005.

[47] Y. Matsumura, A. Iwasawa, T. Kobayashi, T. Kamachi, T. Ozawa, and M. Kohn, "The reactivity of α-oxoaldehyde with reactive oxygen species in diabetes complications," Journal of Clinical Biochemistry and Nutrition, vol. 52, no. 2, pp. 128–132, 2013.

[48] H. D. Dakin and H. W. Dudley, "An enzyme concerned with the formation of hydroxy acids from ketonic aldehydes," The Journal of Biological Chemistry, vol. 14, pp. 155–157, 1913.

[49] P. J. Thornalley, “The glyoxalase system in health and disease,” Molecular Aspects of Medicine, vol. 14, no. 4, pp. 287–371, 1993.

[50] P. J. Thornalley, "Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors," Chemico-Biological Interactions, vol. 111-112, pp. 137–151, 1998.

[51] S. P. Baba, O. A. Barski, Y. Ahmed et al., "Reductive metabolism of AGE precursors: a metabolic route for preventing AGE accumulation in cardiovascular tissue," Diabetes, vol. 58, no. 11, pp. 2486–2497, 2009.

[52] D. L. van der Jagt, L. A. Hunsaker, B. S. Young, and W. M. Brown, "Aldo-keto reductase-catalyzed detoxication of endogeneous aldehydes associated with diabetic complications," ACS Symposium Series, vol. 865, pp. 23–35, 2003.

[53] R. J. Kraemer and R. A. Deitrich, "Isolation and characterization of human liver aldehyde dehydrogenase," Journal of Biological Chemistry, vol. 243, no. 24, pp. 6402–6408, 1968.

[54] N. Rabbani and P. J. Thornalley, "The critical role of methylglyoxal and glyoxalase I in diabetic nephropathy," Diabetes, vol. 63, no. 2, pp. 50–52, 2014.

[55] P. J. Beisswenger, S. K. Howell, G. B. Russell, M. E. Miller, S. S. Rich, and M. Mauer, "Early progression of diabetic nephropathy correlates with methylglyoxal-derived advanced glycation end products," Diabetes Care, vol. 36, no. 10, pp. 3234–3239, 2013.

[56] M. K. Arora and U. K. Singh, "Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update," Vascular Pharmacology, vol. 58, pp. 259–271, 2013.

[57] E. N. Taylor and G. C. Curhan, "Determinants of 24-hour urinary oxalate excretion," Clinical Journal of the American Society of Nephrology, vol. 3, no. 5, pp. 1453–1460, 2008.

[58] B. H. Eisner, S. P. Porten, S. K. Bechis, and M. L. Stoller, "Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers," The Journal of Urology, vol. 183, no. 6, pp. 2244–2248, 2010.

[59] A. O. Kadlec, K. Greco, Z. C. Fridirici, S. T. Hart, T. Velloso, and T. M. Turk, "Metabolic syndrome and urinary stone composition: what factors matter most?" Urology, vol. 80, no. 4, pp. 805–810, 2012.

[60] S. T. Cho, S. I. Jung, S. C. Myung, and T. H. Kim, "Correlation of metabolic syndrome with urinary stone composition," International Journal of Urology, vol. 20, pp. 208–213, 2013.